Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 71.28 USD 0.32% Market Closed
Market Cap: 11.3B USD
Have any thoughts about
Bio-Techne Corp?
Write Note

Net Margin
Bio-Techne Corp

14.5%
Current
21%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
14.5%
=
Net Income
168.1m
/
Revenue
1.2B

Net Margin Across Competitors

Country US
Market Cap 11.3B USD
Net Margin
15%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 196.3B USD
Net Margin
14%
Country US
Market Cap 170.3B USD
Net Margin
18%
Country KR
Market Cap 66.5T KRW
Net Margin
24%
Country CH
Market Cap 37.6B CHF
Net Margin
9%
Country US
Market Cap 38.5B USD
Net Margin
22%
Country US
Market Cap 36.7B USD
Net Margin
9%
Country US
Market Cap 26.4B USD
Net Margin
21%
Country US
Market Cap 23B USD
Net Margin
17%
Country US
Market Cap 22.3B USD
Net Margin
-36%
No Stocks Found

Bio-Techne Corp
Glance View

Market Cap
11.3B USD
Industry
Life Sciences Tools & Services

Bio-Techne Corp. stands at the forefront of scientific progress, intertwining innovation with essential biotechnology solutions. Founded in 1976 and headquartered in Minneapolis, the company has evolved from its roots in producing protein research reagents to a diversified powerhouse, supporting the life sciences and clinical diagnostics sectors. Bio-Techne's expansive portfolio encompasses cutting-edge tools and technologies allowing researchers to delve deeper into cellular analysis, gene expression, and molecular diagnostics. With brands like R&D Systems, Novus Biologicals, and ProteinSimple under its belt, the company empowers scientists worldwide to unlock new discoveries, simulate complex biological processes, and ultimately contribute to advancements in healthcare and life sciences. For investors, Bio-Techne presents a compelling opportunity as it operates in a rapidly growing market fueled by increasing demand for precision medicine and advanced research capabilities. The company has demonstrated robust financial performance, marked by consistent revenue growth and healthy profit margins, driven by its commitment to research and development. As Bio-Techne continues to expand its product offerings and enhance its technological capabilities through strategic acquisitions, it stands poised to capture greater market share and drive shareholder value. With a seasoned management team guided by a focus on innovation and customer-centric solutions, Bio-Techne is not just responding to market trends but actively shaping the future of biotechnology.

TECH Intrinsic Value
54.19 USD
Overvaluation 24%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
14.5%
=
Net Income
168.1m
/
Revenue
1.2B
What is the Net Margin of Bio-Techne Corp?

Based on Bio-Techne Corp's most recent financial statements, the company has Net Margin of 14.5%.